RX.V - BioSyent Inc.

TSXV - TSXV Delayed Price. Currency in CAD
7.00
-0.12 (-1.69%)
At close: 10:38AM EST
Stock chart is not supported by your current browser
Previous Close7.12
Open7.04
Bid6.65 x 0
Ask7.00 x 0
Day's Range7.00 - 7.13
52 Week Range5.51 - 8.88
Volume1,600
Avg. Volume4,653
Market Cap95M
Beta (5Y Monthly)0.31
PE Ratio (TTM)20.53
EPS (TTM)0.34
Earnings DateNov 20, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.75
  • GlobeNewswire

    BioSyent Announces Renewal of Normal Course Issuer Bid

    BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase for cancellation up to 800,000 of its common shares (“Shares”) over a 12-month period, representing approximately 5.89% of the Shares outstanding as of December 11, 2019.

  • Should You Be Impressed By BioSyent Inc.'s (CVE:RX) ROE?
    Simply Wall St.

    Should You Be Impressed By BioSyent Inc.'s (CVE:RX) ROE?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • GlobeNewswire

    BioSyent Signs Exclusive Agreement for Pain Management Products

    BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive License and Supply Agreement (“the Agreement”) with AFT Pharmaceuticals (“AFT”, NSX: AFT, ASX: AFP) for a portfolio of new pain management products for the Canadian market. Health Canada has recently approved the first form of Combogesic® and BioSyent Pharma Inc. intends to launch the product in 2020. Under the Agreement, BioSyent Pharma Inc. also has rights to additional forms of Combogesic® - some of which have been approved in other countries and for which it intends to seek approval in Canada.

  • Thomson Reuters StreetEvents

    Edited Transcript of RX.V earnings conference call or presentation 20-Nov-19 10:59am GMT

    Q3 2019 Biosyent Inc Earnings Call

  • GlobeNewswire

    BioSyent Releases Results for Third Quarter and First Nine Months of 2019

    MISSISSAUGA, Ontario, Nov. 20, 2019 -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and nine months ended.

  • GlobeNewswire

    BioSyent Schedules Q3 and YTD 2019 Earnings Release for November 20, 2019

    BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2019 on Wednesday, November 20, 2019. A presentation on the Company’s third quarter and year-to-date 2019 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

  • Should You Worry About BioSyent Inc.'s (CVE:RX) CEO Pay?
    Simply Wall St.

    Should You Worry About BioSyent Inc.'s (CVE:RX) CEO Pay?

    René Goehrum became the CEO of BioSyent Inc. (CVE:RX) in 1999. First, this article will compare CEO compensation with...

  • Thomson Reuters StreetEvents

    Edited Transcript of RX.V earnings conference call or presentation 23-Aug-19 10:59am GMT

    Q2 2019 Biosyent Inc Earnings Call

  • Should You Be Worried About Insider Transactions At BioSyent Inc. (CVE:RX)?
    Simply Wall St.

    Should You Be Worried About Insider Transactions At BioSyent Inc. (CVE:RX)?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • GlobeNewswire

    BioSyent Named to the Growth 500 Ranking of Canada's Fastest-Growing Companies for Seventh Consecutive Year

    BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been named to the 31st annual Growth 500 ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s.  The Growth 500 ranks Canada’s top private and public companies based on five-year revenue growth. Based on a five-year revenue growth rate of 176% (2013 - 2018), BioSyent was named as one of Canada’s Fastest-Growing Companies on the 2019 Growth 500 list.  This is the seventh consecutive year that BioSyent has been named to the Growth 500 list – formerly known as the PROFIT 500.

  • GuruFocus.com

    When Being Certain Isn't Enough

    At Nintai, it's simply not possible to reduce risk enough where you are totally comfortable with your investment. Here's a case to show you why Continue reading...

  • GlobeNewswire

    BioSyent Releases Q2 and H1 2019 Results

    MISSISSAUGA, Ontario, Aug. 23, 2019 -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30,.

  • The BioSyent (CVE:RX) Share Price Is Down 34% So Some Shareholders Are Getting Worried
    Simply Wall St.

    The BioSyent (CVE:RX) Share Price Is Down 34% So Some Shareholders Are Getting Worried

    Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...

  • GlobeNewswire

    BioSyent Schedules Q2 and H1 2019 Earnings Release for August 23, 2019

    BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2019 on Friday, August 23, 2019.  A presentation on the Company’s second quarter and first half 2019 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.  BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

  • Despite Its High P/E Ratio, Is BioSyent Inc. (CVE:RX) Still Undervalued?
    Simply Wall St.

    Despite Its High P/E Ratio, Is BioSyent Inc. (CVE:RX) Still Undervalued?

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a...

  • An Intrinsic Calculation For BioSyent Inc. (CVE:RX) Suggests It's 49% Undervalued
    Simply Wall St.

    An Intrinsic Calculation For BioSyent Inc. (CVE:RX) Suggests It's 49% Undervalued

    How far off is BioSyent Inc. (CVE:RX) from its intrinsic value? Using the most recent financial data, we'll take a...

  • GlobeNewswire

    BioSyent to Present at Raymond James Life Sciences and MedTech Conference

    TORONTO, June 17, 2019 -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that Mr. René Goehrum, President and CEO of BioSyent, will be presenting at the.

  • GlobeNewswire

    BioSyent Releases Results for Q1 2019

    TORONTO, May 29, 2019 -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three months ended March 31, 2019. Key highlights.

  • GlobeNewswire

    BioSyent Schedules Q1 2019 Earnings Release for May 29, 2019

    BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2019 on Wednesday, May 29, 2019.  A presentation on the Company’s first quarter 2019 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. As of the date of this press release, the Company has 14,097,015 common shares issued and outstanding.

  • Simply Wall St.

    Is BioSyent Inc. (CVE:RX) A High Quality Stock To Own?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • GlobeNewswire

    BioSyent Announces Health Canada Approval of New Women’s Health Product

    TORONTO, May 13, 2019 -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Tibella® (tibolone), indicated for the short-term.

  • GlobeNewswire

    FeraMAX® Named #1 by Canadian Physicians and Pharmacists for Fourth Consecutive Year

    BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the fourth consecutive year, FeraMAX®  has been named the #1 recommended iron supplement brand in a national survey of Canadian physicians and pharmacists. The 2019 Survey on OTC Counselling & Recommendations was conducted by RKI: Research+Knowledge+Insights and the following publications within the EnsembleIQ Healthcare Group: Pharmacy Practice + Business, The Medical Post, Profession Santé, CanadianHealthcareNetwork.ca, and ProfessionSanté.ca.  This annual online survey was conducted between July 2018 and October 2018 with Canadian physicians and pharmacists.  In total, 1,331 surveys were completed by pharmacists and 594 surveys were completed by physicians.  FeraMAX® was named by 50% of pharmacists and 41% of physicians surveyed as the most recommended iron supplement brand to Canadian patients.

  • How Much is BioSyent Inc.'s (CVE:RX) CEO Getting Paid?
    Simply Wall St.

    How Much is BioSyent Inc.'s (CVE:RX) CEO Getting Paid?

    René Goehrum became the CEO of BioSyent Inc. (CVE:RX) in 1999. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth that the business demonstrates...

  • Thomson Reuters StreetEvents

    Edited Transcript of RX.V earnings conference call or presentation 20-Mar-19 10:59am GMT

    Q4 2018 Biosyent Inc Earnings Call